BACKGROUND: Stem cell research in the endometrium and myometrium from animal models and humans has led to the identification of endometrial/myometrial stem cells and their niches. This basic knowledge is beginning to be translated to clinical use for incurable uterine pathologies. Additionally, the implication of bone marrow-derived stem cells (BMDSCs) in uterine physiology has opened the field for the exploration of an exogenous and autologous source of stem cells.
Introduction
Since ancient times, philosophers and scientists have theorized about the possibility of immortality. Physical immortality, or a state of avoiding death, remains utopic; however, biological immortality exists for some tissues and organs and such systems can be used as a model to better understand rejuvenation. Indeed, a tissue or organ that does not experience aging, maintaining its function throughout the lifetime and even after its separation from the body (by in vitro perfusion or transplantation), can be considered as biologically immortal (Rando, 2006) .
In this sense, the human uterus as a reproductive organ is immortal: menstrual function and the ability to achieve pregnancies resulting in documented livebirths can be maintained throughout the lifespan with proper hormonal replacement therapy (Lydic et al., 1996) . In 1988, the Bulleti group reported the achievement of a pregnancy, maintained through the first trimester, in an in vitro human perfused uterus obtained after hysterectomy (Bulletti et al., 1988) . Decades later, the Brannström group reported the first successful live birth following uterine transplantation (Brännström et al., 2015) .
Biological immortality of the uterus as a reproductive organ is enabled by the existence of a remarkable endometrial stem cell (EndoSC) population presumably located in the basalis. In the myometrium, specific cell populations with multipotent stem cell properties have been recently identified in murine and human models, and have been implicated in the plasticity of this organ and in the development of leiomyomas, an unsolved common gynecological pathology (Ono et al., 2007; Chang et al., 2010; Maruyama et al., 2010; Mas et al., 2015 Mas et al., , 2017 Ono and Maruyama, 2015) . In the little over a decade since the first evidence of EndoSC (Chan et al., 2004) , the field has begun to move from the bench to the bedside (Santamaria et al., 2016) with the potential translational application of basic discoveries to treat incurable uterine pathologies.
In this comprehensive review, we aim to summarize the progress that has been made from the characterization of endometrial and myometrial stem/progenitor cells in both human and mouse models to their clinical application. Just as important as the stem cell population is the stem cell niche, the specific microenvironment in which these progenitor cells regulate their division and cell fate decisions. The current state of advanced stem cell therapy in the treatment of Asherman syndrome and atrophic endometrium will be reviewed and new clues in understanding myometrial pathology will be presented. Finally, recent advances in tissue engineering based on the creation of novel three-dimensional (3D) scaffolds, or decellularisation, have opened new perspectives-as well as ethical dilemmas-for the field of uterine transplantation.
Methods
A comprehensive search of the PUBMED database and Google Scholar was conducted with the search terms 'endometrial/myometrial or uterine stem cells' up to December 2017. Our goal was to identify peerreviewed literature related to the contribution of bone marrow (BM) and endometrial and myometrial uterine stem cells and their niches to the physiological regenerative potential as well as their implications in pathologies and therapies of the human uterus. For this purpose, we have assessed the relevance of each article in relation to the main subject areas of this review, based on the title and abstract. Studies from both animal models and humans were reviewed for this manuscript.
EndoSCs and their niche

Identifying EndoSCs in animal models
Stem cells undergo asymmetric division to allow for self-renewal and to produce daughter cells that differentiate into tissue-specific cell types . EndoSCs resident in the endometrium maintain endometrial regeneration, but bone marrow-derived stem cells (BMDSCs) also contribute to this regeneration.
The labeling retention (LR) method involving the incorporation of the thymidine analog 5-bromo-2′-deoxyuridine (BrdU) is a standard for identifying somatic stem cells (SSCs) in different tissues and organs. Although it cannot be used for studies in humans, LR is a valuable tool in animal models. When newborn mice are treated with repeated injections of BrdU, all dividing cells will incorporate BrdU into newly synthesized DNA during the replication phase of the mitotic cycle, thus labeling all newly formed cells. This DNA label marks the proliferative history of the cell, since slow-cycling cells retain BrdU for longer than more rapidly dividing cells (Bickenbach, 1981; Morris et al., 1985; Bickenbach et al., 1986; Cotsarelis et al., 1990; Bickenbach and Chism, 1998; Morris and Potten, 1999) .
Label-retaining cells (LRCs) have been detected in multiple tissues, including hair follicles (Morris and Potten, 1999; Taylor et al., 2000) , skin (Bickenbach and Chism, 1998) , the haematopoietic system (Zhang et al., 2003) , adult renal papilla (Oliver et al., 2004) and liver (Li et al., 2010) . This long-term labeling approach was also used to localize the quiescent or slow-cycling cells of the murine endometrium (Chan and Gargett, 2006; Cervelló et al., 2007) . These two independent studies presented the first reports of the presence of LRCs in the murine endometrium. After 8 weeks of labeling chase, Chan et al. identified a small population of epithelial LRCs (3%) located mainly in the luminal epithelium, with cells occasionally observed in the glandular epithelium. Epithelial LRCs were negative for several phenotypic markers, including stem cell antigen (SCA-1), the leukocyte marker CD45, and oestrogen receptor-α (ER-α). After 12 weeks, a small population of stromal LRCs (6%) was identified at the endometrial-myometrial junction near the blood vessels. The stromal LRCs did not express typical stem cell markers (e.g. SCA-1) or leukocyte markers indicating a non-haematopoietic origin; however, some expressed ER-α, suggesting they are responsive to hormonal stimulation. In a second murine study, Cervelló et al. (2007) identified LRCs mainly in the stromal compartment, as the epithelial labeling was lost around 3 weeks of age. The population of stromal LRCs slowly decreased from 8.6 ± 5.3% at postnatal Day 49 to 1.7 ± 0.8% at postnatal Day 112 (Cervelló et al., 2007; Cervelló and Simón, 2009 ). This population co-localized with cells expressing the stem cell factor receptor c-Kit (CD117) (Sperling et al., 1997) . Expression of c-Kit has been described in several types of stem cells, including EndoSCs (Cho et al., 2004; Shin et al., 2014) . In the adult endometrium, c-Kit expression was restricted to the lower region of the stroma and marked 0.32% of the LRCs. Some of the LRC population expressed POU5F1 (OCT-4), a marker of pluripotent stem cells, including embryonic and germ stem cells (Scholer, 1991; Goodell et al., 1996) . In adult mice, the expression of POU5F1 was restricted to cells in the lower region of the endometrial stroma representing 0.19% of LRCs.
Taylor´s group first identified stem cell migration from BM to the endometrium (Taylor, 2004) . His group subsequently used mouse models to demonstrate different mechanisms by which BMDSCs can engraft in the murine endometrium (Du and Taylor, 2007; Du et al., 2012; Alawadhi et al., 2014) . The first study by Alawadhi et al. (2014) demonstrated significant BMDSC engraftment in the endometrium in a mouse model of Asherman syndrome induced by traumatizing the uterus in a reproducible manner. They evaluated stem cell recruitment and pregnancy after BMDSC transplantation from male donors. In this experiment, the Y chromosome-bearing CD45 negative (CD45-) cells represented less than 0.1% of total endometrial cells. The number of Y+CD45-cells identified in the damaged uterus was 2-fold higher compared to the uninjured controls. Further, 90% of mice in the BMDSC transplant group conceived over several cycles compared to 30% of pregnancies in the non-transplanted group, while all mice in the uninjured control group conceived. Thus, fertility was improved after the BMDSC transplant in the induced Asherman syndrome mouse model, demonstrating a functional role for these cells in uterine repair and suggesting BMDSC transplantation as a potential novel treatment for Asherman syndrome. We have recently conducted a randomized trial in mice comparing BMDC to EndoSC for regeneration of the endometrium (Liu et al., 2018) . In this study, endometrial cells were less effective than BMDSCs in repopulating the endometrium. Based on these findings, we hypothesize that endogenous EndoSC are partially differentiated towards an endometrial cell fate while BMDC are still multipotent and likely might differentiate to early precursor cells that can fully replace all endometrial cell types. Partially-differentiated endometrial cells may have a restricted cell fate and cannot replace some of the stem cells needed for optimal endometrial restoration. In that same study (Liu et al., 2018) , we compared direct intrauterine injection of BMDSC to intravenous administration. The functional result of peripheral administration of stem cells was superior to direct injection. An essential aspect of stem cell engraftment is incorporation into the stem cell niche-a supportive environment where the appropriate paracrine signals maintain the undifferentiated and multipotent state. Injection into the endometrium, subendometrial space or myometrium resulted in fewer BMDSC incorporated into the endometrium, while the stem cells likely migrate to the appropriate niche through the circulation. On these grounds, we suspect that the initial stem cell niche is perivascular and homing to this niche takes place exclusively through the circulation. These animal studies suggest that stem cell therapies should preferentially use non-endometrial stem cells that are still maximally multipotent and that the optimal delivery is through the vasculature.
Similarly, Simon's group used an irradiated mouse model to test the extent to which different types of bone marrow-derived cellsunfractionated BM cells, haematopoietic progenitor cells, endothelial progenitor cells and mesenchymal stem cells-could regenerate murine endometrium . All cell subtypes transplanted after nonlethal irradiation were detected in the murine endometrium, albeit at low percentages. Grafted cells conferred a beneficial effect that was probably due to the induction of paracrine factors allowing neighboring cells to enhance the restoration of damaged endometrial tissue. This hypothesis was corroborated in a murine model of Asherman syndrome in which human CD133+ BMDSCs were injected either systemically or locally, and acted via secreted paracrine factors to promote endometrial proliferation (Cervelló et al., 2015) .
Finally, Taylor's group has shown that BMDSCs can similarly migrate to the endometrium and engraft in endometriosis (Du and Taylor, 2007; Sasson and Taylor, 2008) . Endometriosis creates an inflammatory environment where multiple chemokines, including C-X-C motif chemokine ligand 12 (CXCL12), are produced in abundance . High CXCL12 levels attract circulating BMDSCs, which engraft at the endometriosis foci in higher numbers than in normal endometrium (Sakr et al., 2014) . In fact, endometriosis foci aggressively compete with the endometrium for a limited supply of circulating BMDSCs, and a smaller number of stem cells engraft in the eutopic endometrium in cases of endometriosis, potentially limiting the ability to repair uterine damage (Figueira et al., 2011) . The long-term effect is likely defective endometrium with limited receptivity, as has been observed in endometriosis. Certain current medical therapies function, at least in part, by reducing the ability of endometriosis to recruit stem cells and restoring stem cell flux to the uterus . For instance, drosperinone (Makabe et al., 2017) , dinogest (Nirgianakis et al., 2016) and even progestrone (Ruiz et al. 2010) administration have the common effect of silencing cytokine expression and reducing the recruitment of stem cells in endometriosis. The restoration of BMDSC flux to the uterus and subsequent uterine repair likely explains the improved fertility seen in ART after long-term medical suppression of endometriosis. Additionally, epigenetic mechanisms such as microRNA (miRNA) could promote susceptibility to develop endometriosis later in life through the regulation of the stem cell population. In fact, several studies have demonstrated that miR-200b (Eggers et al., 2016) and miR-145 inhibit the proliferation, invasiveness and stem cell phenotype of an in vitro endometriosis model (Adammek et al., 2013) .
Human EndoSCs
Over the past 15 years, different techniques and stem cell markers have been used to identify the human EndoSC population. Unfortunately, no consensus concerning unequivocal EndoSC markers has been reached. Yet, as in mice, human endometrium is believed to possess bothendogenous and exogenous sources of SSCs that are key for understanding its extraordinary regenerative capability.
Endogenous SSCs derive from the tissue-resident reserve. EndoSCs include epithelial, stromal and endothelial cells, and all may contribute to the rapid endometrial regeneration as Gargett and Masuda described (Gargett and Masuda, 2010) . In the absence of specific phenotypic markers for EndoSCs, these cells are typically defined by their functional properties. Putative human EndoSCs have been identified based on properties such as clonogenicity (Tanaka et al., 2003; Chan et al., 2004; Schwab et al., 2005 Schwab et al., , 2008 Dimitrov et al., 2008; Cervelló and Simón, 2009; Gargett et al., 2009; Kyurkchiev et al., 2010; Masuda et al., 2010 Masuda et al., , 2012 Oliveira et al., 2012; Murakami et al., 2013) , long-term culturing capability (Kato et al., 2007; Schwab and Gargett, 2007; Masuda et al., 2010; Cervelló et al., 2011) , multilineage differentiation potential (Wolff et al., 2007; Cervelló et al., 2010; Cervelló et al., 2011; Santamaria et al., 2011; Schüring et al., 2011; Ai et al., 2012; Miyazaki et al., 2012; Gargett et al., 2016) and expression of stem cell markers (Cho et al., 2004; Schwab and Gargett, 2007; Götte et al., 2008; Aghajanova et al., 2010; Gargett and Masuda, 2010; Valentijn et al., 2013; Chen et al., 2014; Cervelló et al., 2017) . The final proof-of-concept used the side population (SP) method to demonstrate in vivo reconstruction of human endometrium in a xenograft animal model (Cervelló et al., 2010; Cervelló et al., 2011; Masuda et al., 2012; Miyazaki et al., 2012) ( Table I) .
The SP method identifies undifferentiated/stem cells in adult organs or tissues by their ability to extrude a DNA-binding dye (Hoechst 33 342) via the ATP-binding cassette transporter. Although originally described as a marker of BM stem cells (Goodell et al., 1996) , the SP method has been used to identify stem cells from different organs and tissues, including the mammary gland (Smalley and Clarke, 2005) , skin (Larderet et al., 2006) and myometrium (Ono et al., 2007) . Two independent groups demonstrated that SP cells derived from human endometrium could represent the EndoSCs population due to their stem cell properties (Tsuji et al., 2008; Cervelló et al., 2010; Cervelló et al., 2011; Masuda et al., 2015) . In the Masuda et al. (2010) study, the human endometrial SP cells (mixture of epithelial and stromal fractions) represented 2.8 ± 0.3% SD of endometrial cells. A clonogenic assay revealed three distinct types of colonies: fibroblastoid stromal, endothelial and epithelial clones. To investigate the stem cell-like regenerative capabilities of SP cells in vivo, they transplanted this population under the kidney capsule of immunocompromised mice. Although the reconstitution efficiency was low, they described human endometrium-like tissue reconstruction with a glandular structure in some of the injected mice. Simon's group isolated the human endometrial SP from the epithelial and stromal compartments separately, representing 1.68 ± 0.27% of the live cell population in the epithelium and 0.39 ± 0.06% in the stroma. Marker expression suggested that the stromal and epithelial SP cells have a mesenchymal phenotype (CD90+ and CD105+). Further, the telomerase activity pattern revealed that SP cells showed an intermediate pattern between pluripotentent and oligopotent cells. Telomerase activity is not detected in most somatic cells with the exception of embryonic tissues and stem cells. The capability of SP cells to differentiate in vitro into mesodermal lineages (osteo-and adipogenic differentiation) was also demonstrated. Finally, human endometrial reconstruction, although at low efficiency, was observed after subcutaneous and kidney capsule injection of human SP cells in nonobese diabetic-severely compromised immunodeficient (NOD-SCID) mice (Cervelló et al., 2010 , Cervelló et al., 2011 .
An exogenous source of stem cells, BMDSCs are able to repopulate various non-haematopoietic tissues (Pittenger et al., 1999) . In 2004, Taylor's group first reported BMDSC recruitment to the human uterus after BM transplantation (Taylor, 2004) . A mismatched HLA type was used to mark the BM-derived cells, and a high percentage of BMDSCs was noted in the endometrium after irradiation, chemotherapy and BM transplant. BMDSCs differentiated into both stromal and epithelial cells, but the BM-derived stromal cells were more abundant. The number of cells increased with time from transplant, suggesting that a gradual accumulation of BM cells occurs over time. The finding that up to~50% of cells could be of BM origin suggested the potential for significant long-term regeneration of endometrium conditions.
Several publications have since supported Taylor's theory. Ikoma and colleagues reported the unexpected plasticity of BM cells: they could give rise to a functional endometrium (with markers of differentiated epithelial and stromal cells), resulting in successful pregnancies in two of three patients analyzed (Ikoma et al., 2009) . Following BM transplantation from male donors to female recipients, XY donorderived differentiated endometrial cells were found in the endometrium of recipients, suggesting that endometrial renewal is a highly plastic process . These basic findings have paved the way for translation of the exogenous source of human EndoSCs as advanced stem cell therapy in cases of refractory Asherman syndrome and atrophic endometrium (Santamaria et al., 2016) , as presented in the section 'Current State of Advanced Stem Cell Therapy in EndoSC Niche Pathologies'.
The EndoSC niche
Endometrium is a very dynamic tissue, where endometrial breakdown and repair occur simultaneously, side by side, under a carefully controlled balance in every menstrual cycle (Evans and Salamonsen, 2012 ) that has been described as orderly inflammation (Nathan and Ding, 2010) . After menstruation the endometrium must efficiently repair to allow an embryo to implant. The processes involved in endometrial repair include inflammation, angiogenesis, tissue formation and tissue remodeling (Maybin and Critchley, 2015) . Certain studies suggest that epithelial cells grow from the necks of the glands to meet migrating cells from other glands, forming a new luminal surface and completing the uterine epithelization that seems to be required before the stromal compartment can respond to ovarian steroids (Bigsby, 2002) . Adult stem cells play a key role in this homeostatic process, balancing between self-renewal and differentiation (Gargett, 2007) .
As Schofield (1978) described in the 1970's, stem cells reside in specialized microenvironments, also called stem cell niches, which regulate their division and cell fate decisions. The niche has since been redefined as a dynamic system where stem cells interact with different components in the microenvironment such as cells (stem cells, differentiated cells), secreted factors (chemokines, hormones, growth factors receptors), extracellular matrix (ECM) (collagen fibers, fibronectin), physical factors, hypoxia/metabolism and the general milieu (inflammation, scarring, hormone-rich) (Lane et al., 2014) . The dynamic niche system supports the idea that stem cells reside in specific locations receiving different stimuli that will determine stem cell behavior (Ferraro et al., 2010) (Fig. 1) .
In humans, an important regulatory niche encompasses the perivascular space promoting the renewal of the endometrial superficial layer around the rapidly growing spiral arterioles (Murakami et al., 2014) . This niche promotes cyclical endometrial renewal from endogenous SSC recruitment and homing of migrating exogenous SSCs (Gargett, 2007; Cervelló et al., 2017) . The importance of the vascular niche for EndoSCs has been demonstrated in the literature (for detail see Gargett et al., 2015) . The EndoSC niche could be the target for specific therapies that enable regeneration of the endometrial tissue in cases of niche pathologies such as Asherman syndrome or endometrial atrophy (EA).
Myometrial stem cells and their niche
Stem cells in human myometrium
During a woman's reproductive life, the uterus undergoes pregnancyinduced expansion mainly composed of myometrial cells; this process can be repeated multiple times (Burroughs et al., 2000; Ono et al., 2012) . Indeed, the uterus increases up to 1000-fold in volume and 20-fold in weight (Maruyama et al., 2010; Ono and Maruyama, 2015) . Based on this remarkable plasticity and its exceptional regenerative potential, the myometrial tissue could suggest the existence of SSCs (Ono et al., 2007 , Teixeira et al., 2008 . Several lines of evidence corroborate the idea that SSCs are present in the female reproductive tract (Ono et al., 2008; Maruyama et al., 2010; Mas et al., 2014) , and their presence is critical for uterine regeneration and tissue remodeling.
The first evidence for the existence of a myometrial stem cell (MyoSC) population relates to the embryological development of the female reproductive tract (Teixeira et al., 2001) . Considering that the eventual formation of the uterus is the result of the proliferation of 
In Vivo Reconstruction
The gold standard assay of somatic stem cell activity involves in vivo reconstitution of the tissue from which the putative stem cell population was derived. mesenchymal cells (Hu and Spencer, 2005; Mas et al., 2014) , the internal mesenchyme would correspond to the endometrial stroma of the adult uterus, while the external mesenchyme would give rise to adult myometrium (Ramsey, 1994; Fujii et al., 1999; Kurita et al., 2001) . Additional evidence for the existence of MyoSCs is the tissue growth during pregnancy (Maruyama et al., 2010; Ono and Maruyama, 2015) . This uterine growth is due to an increase in the number of cells (myometrial hyperplasia) during the early stages of gestation; during the advanced stages of gestation, an increase in cell size (hypertrophy) occurs (Ramsey, 1994; Shynlova et al., 2009) . After delivery, the uterus involutes because of extensive apoptosis of myometrial cells, but is succeeded by regeneration to maintain organ integrity. Although the above changes are remarkable, it does not seem likely that repeated expansion of the uterus could be due entirely to cycles of hyperplasia and hypertrophy of differentiated cells, but rather new myometrial cells must be generated when the uterus returns to its basal status after pregnancy. Therefore, it is plausible that there exists a population of stem/progenitor cells in the myometrium that sustains cell proliferation mechanisms responsible for expansion and remodeling of the pregnant uterus. Indeed, several studies have demonstrated that myometrial Hoechst-stained cells contain a small fraction of SP cells resting in G 0 phase, a characteristic of stem cells that allows them to persist (Goodell et al., 1996; Ono et al., 2007; Chang et al., 2010) . However, because of the lack of specificity of this technique (Maruyama et al., 2010; Golebiewska et al., 2011) , novel approaches are emerging to identify specific MyoSC surface markers (Drosch et al., 2014; Ono and Maruyama, 2015; Mas et al., 2017) . Ono and Maruyama (2015) have identified CD49f and CD34 as potential stem cell markers in human myometrium. Simultaneously, Simon's group has demonstrated that the combination of the surface markers STRO-1 and CD44 can be used to enrich a subpopulation of myometrial cells exhibiting the key characteristics of tumor-initiating cells (TICs) (Mas et al., 2015) . In both cases, cells isolated with these markers maintain an undifferentiated state, have a high capacity of cell colony formation in vitro under hypoxic conditions, and have the ability to differentiate in vitro to adipocytes, osteocytes and chondrocytes. The cells are also capable of reconstructing myometrial tissue in vivo in xenograft animal models, corroborating the validity of CD49f/CD34 and STRO-1/CD44 as potential markers of MyoSCs, although their biological importance and the relevance of differential expression among these cells remains to be elucidated (Mas et al., 2015; Ono and Maruyama, 2015) .
The MyoSC niche and its regulation
During development, the highly plastic state of stem/progenitor cells creates the required dynamic system for cell and tissue homeostasis through the stem cell niche. Specifically, the MyoSC niche is located within a precise anatomic location, in this case the myometrium, where MyoSCs, usually in the G 0 phase, are able to maintain, regenerate, and/or repair myometrial tissue through extrinsic factors that modulate proliferation and differentiation (Mas et al., 2014) . There is growing evidence that low-oxygen conditions could be the stimulus that permits tissue-specific stem cell survival and growth (Ono et al., 2007; Mohyeldin et al., 2010; Mas et al., 2012) . In fact, although MyoSCs did not proliferate in vitro in a normoxic (20% O 2 ) environment, they did grow efficiently under a 2% oxygen tension, being able to differentiate into smooth muscle cells. Other in vivo studies in murine models have demonstrated, using biochemical probes, that during pregnancy hypoxia in the myometrium could be induced by mechanical stretching of the uterine wall (Shynlova et al., 2010) . Therefore, it is possible that pregnancy-induced mechanical stretching leads to hypoxia and may promote the proliferation of MyoSCs contributing to uterine enlargement and remodeling. Additionally, Mas and by different components such as cellular factors, the environmental milieu (e.g. macrophages), the extracellular matrix (e.g. collagen fibers), a protective environment, hypoxia and metabolism (e.g. glucose, low-oxygen concentration), physical factors (e.g. elasticity, volume) and cell-secreted factors (e.g. hormones, growth factors).
colleagues have also demonstrated by using the Eker rat murine model for uterine leiomyoma formation that the cervix was a hypoxic 'niche' and primary site for fibroid development in these animals (96%) (Mas et al., 2017) . In fact, biological effects like low-oxygen tension (2%-5%), or hypoxia, appear to aberrantly activate oestrogen signaling pathways and consequently upregulate secreted frizzledrelated protein 1 (SFRP1), a modulator of WNT signaling that exerts anti-apoptotic effects in leiomyoma but not in myometrial cells (Fukuhara et al., 2002; Ono et al., 2008; Zhou et al., 2011) . These conditions may occur during myometrial contraction and vasoconstriction, contributing to the dysregulation of MyoSC towards TICs, which would proliferate and ultimately contribute to uterine tumourigenesis (Fig. 2) . Nevertheless, in humans there is no clinical evidence to date suggesting that uterine fibroids originate from the cervical niche. Hence, in order to propose the cervix as the singular myometrial niche, further characterization of these differences between animal and human tissues are ongoing in our laboratory, as well as investigating the potential impact of age and anatomical location within the uterus. Cellular events occurring in the MyoSC niche, including proliferation and differentiation, are mediated by local production of growth factors acting through paracrine/autocrine mechanisms (Ciarmela et al., 2011) . The best-studied factors acting on MyoSC and differentiated cells are epidermal growth factor (EGF) (Yeh et al., 1991) , platelet-derived growth factor (Boehm et al., 1990) , transforming growth factor beta (TGF-β) (Dou et al., 1996; Dixon et al., 2000) , activin, and myostatin (Ciarmela et al., 2011) , which act through the activation of the small G-proteins (RAS)-extracellular signalregulated kinases (ERK)/mitogen-activated protein kinases (MAP) and phosphatidylinosite-3 kinase (PI3K)-protein kinase (AKT)-mammalian target of rapamycin (mTOR) pathways as well as the serine/threonine kinase receptors/SMAD pathway. In addition, ovarian hormones help orchestrate events concerning myometrial cellular transformation and turnover, exerting their pro-mitogenic effect by transcriptional mechanisms, and ultimately resulting in leiomyoma pathophysiology (Yin et al., 2007; Ciarmela et al., 2011; Islam et al., 2013; . This evidence is in line with the fact that uterine leiomyomas can have different growth characteristics in the same uterus, which suggest that local and cell-autonomous mechanisms play key roles in the development and growth of these benign tumors (Hanahan and Coussens, 2012; Commandeur et al., 2015) . In this context, the growth of TICs, contributing to uterine leiomyoma development, requires the presence of mature myometrial cells with higher levels of oestrogen and progesterone receptors, suggesting that this action is mediated in a paracrine manner with surrounding cells supporting the self-renewal of TICs Ono et al., 2012) (Fig. 2) . In fact, pregnant myometrium and uterine leiomyomas are both characterized by an extraordinary myometrial growth rate, as well as an increased production of ECM components and the expression of peptides and steroid receptors (Ciarmela et al., 2011) . However, unlike normal post-partum myometrium, uterine leiomyomas fail to regress via apoptosis and to undergo normal dedifferentiation (Walker and Stewart, 2005) . Therefore, although both tissues present dysregulated patterns of cellular differentiation and gene expression, they differ for oestrogen-regulated genes (Shynlova et al., 2009) . Current knowledge also supports that, by signaling through its receptor, progesterone may play a key role in the clonal expansion of TICs into uterine leiomyomas, potentially promoting tumourigenesis by affecting both TICs and differentiated myometrial cells Ono et al., 2012; Bulun, 2013) .
There are critical interactions between the pathways activated by WNT-CTNNB1 and TGFB3, oestrogen/progesterone and stem cell renewal, which may ultimately lead to clonal formation of uterine leiomyomas (Tai et al., 2003; Yamagata et al. 2009; Sinclair et al., 2011) . Indeed, the size and number of these benign tumors driven by β-catenin increase with parity in mice, suggesting that ovarian hormones may interact with the WNT/β-catenin pathway to accelerate tumourigenesis (Tanwar et al., 2009) . In humans, Ono and collaborators also reported in 2013 the critical role for the WNT/β-catenin pathway in the communication between TICs and the surrounding differentiated cells when the latter were treated with oestrogen and progesterone (Ono et al., 2013; . This resulted in secretion of WNT ligands, inducing nuclear translocation of β-catenin in neighboring TICs and activating the expression of growth and proliferation genes. However, the role of steroid hormones as well as the low-oxygen tension in the WNT signaling pathway need to be further clarified.
Developmental errors in the TICs and/or the niche lead to uterine leiomyoma formation Uterine leiomyomas are the most common benign gynecological tumor in women of reproductive age (Parker et al., 2007) . These can present different sizes and be single or multiple, with an estimated average of six to seven per patient (Pritts et al., 2009) . Currently, it is estimated that in the USA~77% of women at childbearing age experience this type of tumor, which can cause health problems such as prolonged menstrual bleeding, severe anemia, infertility and recurrent pregnancy loss (Jacoby et al., 2009 ). Chromosomal and/or genetic alterations are known causes of leiomyoma formation (Cha et al., 2011; Markowski et al., 2011) . In this context, hereditary defects in the fumarate hydratase (FH), Birt-Hogg-Dube (BHD) and tuberous sclerosis complex 2 (TSC2) genes, promote the development of benign tumors (Walker and Stewart, 2005; Islam et al., 2013) . Additionally, recurrent genetic aberrations, such as trisomy of chromosome 12, deletions in 7q, and mutations affecting mediator complex subunit 12 (MED12) and high mobility AT-hook 2 (HMGA2), are implicated in this uterine pathology (Hodge et al., 2009; Velagaleti et al., 2010; Mäkinen et al., 2011) (Table II) . In addition to DNA alteration, the cellular theory of origin has been also introduced (Bulun, 2013) . Genetic abnormalities affecting specific TICs might play pivotal roles in the tumourigenesis of uterine leiomyoma (Ono et al., 2012) (Fig. 2) . Therefore, considering that uterine leiomyomas are monoclonal tumors (Linder and Gartler, 1965; Hashimoto et al., 1995; Wang et al., 2002; Canevari et al., 2005; Zhang et al., 2006; Cai et al., 2007) , it is possible that the dysregulation of MyoSCs or committed cells that acquire stem-like features (TICs) could be responsible for this benign condition (Gargett, 2007; Teixeira et al., 2008; Holdsworth-Carson et al., 2014; Mas et al., 2014) . This hypothesis suggests that TICs are organized hierarchically, similarly to normal tissues, although they would arise from the transformation of SSCs after the acquisition of tissue-specific genetic changes (Jordan et al., 2006) . This situation could confer self-renewal capacity, generating a large population of proliferative cells that would differ from the rest. Therefore, they could initiate the tumourigenic process through a small subset of tumor cells that could ultimately be responsible for the formation, maintenance and growth of the tumor (Fig. 2) .
TICs have been identified and isolated by the SP method in a variety of solid tumors, such as the breast (Al-Hajj et al., 2003) , prostate (Dunning et al., 2011) , pancreas (Li et al., 2007 ) and brain (Galli et al., 2004) . In endometrium, SP cells demonstrated their high tumourigenic potential when injected subcutaneously in NOD/SCID mice with oestrogen implants (Friel et al., 2008) . Thus, accumulated evidence shows that tumor progression could result from the interaction between TICs and their microenvironment (De Wever and Mareel, 2002) , specifically within the stromal compartment (Jordan et al., 2006) . In 2012, two independent groups demonstrated the existence of SP cells with characteristics of TICs in uterine leiomyomas Ono et al., 2012) . The results of these studies suggest that Hoechst-stained and fibrous-derived cells contain a small fraction of SP cells remaining in G 0 , a key feature of stem cells. Data resulting from molecular analysis also revealed that this cell population showed an undifferentiated state by expressing stemness markers such octamer-binding transcription factor 4 (OCT-4), homeobox protein NANOG, DNA (cytosine-5-)-methyltransferase 3 beta (DNMT3B) and growth differentiation factor-3 (GDF3). In addition, low levels of hormone receptors and muscle cell markers were detected, suggesting an indirect paracrine effect across the surrounding differentiated cells in the niche. Furthermore, the isolated TICs from uterine leiomyoma but not myometrium displayed somatic mutations in the MED12 gene (Ono et al., 2012) . This suggests that at least one genetic hit could initially transform a MyoSC to initiate a tumourigenic process that would result in the formation of uterine leiomyomas under the influence of ovarian hormones (Bulun, 2013; Mehine et al., 2013; Tal and Segars, 2014; Fig. 2) .
The majority of uterine leiomyomas can be classified according to one of four types of mutations: MED12 mutations, HMGA2 overexpression, fumarate hydratase (FH) inactivation or collagen alpha (COL4A6-COL4A5) deletions (Simón, 2014; Moravek and Bulun, 2015; Yin et al., 2015) , but only the two first have special interest for the stem cell theory because of their putative input in the creation of TICs (Table II) . Because MED12 limits β-catenin-dependent tissue growth during embryonic development, it is reasonable to hypothesize that the absence or alteration of MED12 in the TIC population could be responsible for β-catenin pathway-dependent tumor growth (Lin et al., 2007; Rocha et al., 2010; Bulun, 2013) . Interestingly, the expression of WNT4 is significantly elevated in uterine leiomyomas with mutations in MED12 compared to controls without mutations (Markowski et al., 2012) . These observations suggest that the mechanism involving the mutation of MED12 and the activation of the WNT/CTNNB1 pathway supports the renewal of TICs, proliferation and fibrosis in uterine leiomyomas (Kim et al., 2006) .
Mutations affecting the expression of HMGA2 in myometrial cells result in an abnormal proliferation of the stem cell niche, leading to the formation of leiomyoma-like tissue (Mas et al., 2014) . Curiously, uterine leiomyomas are deficient in the Let-7 miRNA that targets and suppresses HMGA2 (Peng et al., 2008) . Thus, alterations in the Let-7-HMGA2-p14ARF pathway in TICs could stimulate self-renewal and balance senescence (Bulun, 2013) . However, recent publications demonstrate that MED12 and HMGA2 mutations are independent genetic events in the tumourigenesis of uterine leiomyomas, suggesting that truncated/short HMGA2 could be the key component through which chromosomal rearrangements contribute to human tumor development (Bertsch et al., 2014; .
Finally, epigenetic modifications that are required during development could act on the stem cell niche to alter gene expression, playing a central role in cellular proliferation and differentiation (Yang et al., 2016) . Unfortunately, the high plasticity of stem cells also provides an opportunity for aberrant cellular reprogramming via epigenetic mechanisms, such as DNA methylation, histone modification and miRNA regulation, promoting disease susceptibility later in adulthood (Walker, 2011) . Specifically, the degree of methylation of cytosineguanine sequences in a gene promoter increases and, as consequence, its expression decreases; this is particularly important for differential gene expression in the MyoSCs as well as the TIC population (Jaenisch and Bird, 2003; Bulun, 2013) .
In summary, these findings suggest that uterine leiomyoma development could be associated with disorders of the function, proliferation and fate of a subset of stem cells, opening up new possibilities for understanding the origin and possible treatment of this benign tumor.
Current state of advanced stem cell therapy in EndoSC niche pathologies
Asherman syndrome and endometrial atrophy
Asherman syndrome (AS) is an acquired condition defined by the presence of intrauterine adhesions (IUAs) resulting when the bona fide endometrium is replaced by fibrotic tissues, causing the uterine walls to adhere to one another. This pathology causes symptoms such as infertility, recurrent miscarriage, menstrual abnormalities, pelvic pain and abnormal placentation (Dmowski and Greenblatt, 1969) . The prevalence of AS can vary significantly between countries depending on the aggressiveness of gynecological interventions as well as the incidence of infections such as genital tuberculosis, schistosomiasis, or endometritis. The European Medicines Agency (EMA) has considered the prevalence of AS to be 4.4 cases/10 000 in the European population. Danish studies (Kjer, 2014) and epidemiological public databases, such as DESTATIS, which collects information from all German hospitals, support this prevalence. AS is included in the Orphanet database under the registry ORPHA137686 (EMA, 2014) .
In this pathology, the stromal compartment is largely replaced by fibrous tissue and the glands by inactive cubocolumnar epithelium (Fig. 3) . The functional and basal layers are indistinguishable, are unresponsive to hormonal stimulation, and fibrotic synechiae form across the cavity. The tissue is typically avascular, although thin-walled telangiectatic vessels can be observed (Yaffe et al., 1978) . In severe cases, adhesions may be composed of collagen bundles, fibrous strips or muscle with the same characteristics as normal myometrium, and the cavity may be absent. The endometrium from patients with IUAs contains 50-80% fibrous tissue compared to 13-20% in the normal endometrium. This scarring limits uterine myometrial activity and reduces the perfusion by ovarian steroids, resulting in patches of atrophy (Yaffe et al., 1978) .
Hysteroscopy is considered as the gold standard for diagnosis of AS, providing a real-time view of the uterine cavity-allowing for a meticulous definition of the site, extent and size of any adhesionsand the endometrium. Further, this technique can be performed in the office, making immediate treatment possible in favorable cases.
Fertility restoration after hysteroscopic treatment achieves overall pregnancy rates from 40-63% (Zikopoulos et al., 2004; Conforti et al., 2013) and pregnancy rates ranged from 66% (Xiao et al., 2014) to 30-35% (Pistofidis et al., 1996) in moderate to severe cases of AS in two prospective trials. Moreover, other retrospective studies have reported similar pregnancy rates for moderate and severe cases (Valle and Sciarra, 1988 ; Capella-Allouc et al., 1999). Other Figure 3 Etiopathogenesis of Asherman syndrome and potential mechanisms of action of CD133+ in endometrium. Different factors can cause inflammation and infection that result in defective endometrial healing and destruction of the endometrium, leading to the formation of intrauterine adhesions composed of endometrial tissue, connective tissue or muscular tissue. The figure shows the anatomopathological findings of intrauterine adhesions (x40). Hysteroscopy is considered the gold standard to diagnose intrauterine adhesions. CD133+ may have different mechanisms of action that result in tissue remodeling, tissue regeneration, and angiogenesis. ECM, extracellular matrix; ADAM, a desintegrin and metalloproteinases; TGFB1, transforming growth Factor β-1; SMAD, small mothers against decapentaplegic: a family of proteins critically important for regulating cell development and growth.
unwanted reproductive outcomes of AS include recurrent miscarriage, intrauterine growth restriction and placenta accreta (Deans and Abbot, 2010) . EA is another rare condition in which the endometrium is too thin and unable to grow above 5 mm (Senturk, 2008) . Causes of EA include functional, and usually reversible, factors such as prolonged use of oral contraceptives and tamoxifen, premature ovarian failure, or Kallman Syndrome; in many instances, however, the causes of EA are unknown. This pathology affects 0.5% of infertile women undergoing ART (Senturk, 2008) . Patients with EA have a poor reproductive outcome, and despite the many therapies, such as high doses of estradiol, pentoxifyline, vitamin E, sildenafile, L-arginine or intrauterine perfusion of granulocyte colony stimulating factor (G-CSF), none has proven effective (Sher, 2002; Okusami et al., 2007; Gleicher et al., 2011) .
Uterine stem cell therapy, from the bench to the bedside BM has an organized and structured anatomical architecture that promotes interaction among stem cells and a regulatory microenvironment composed of adipocytes, fibroblasts, and endothelial cells as well as lymphocytes and macrophages (Weiss and Geduldig, 1991; Hoffman et al., 2000) . BMDSCs interact with the stroma of the BM through adhesion molecules such as very late antigen-4 and cytokine receptors that bind to cytokines associated with the membrane or ligands binding to the ECM. Glycoproteins such as G-CSF can interact with the ECM of the BM, decreasing the attachment of BMDSCs to the stroma and thus promoting their release into the bloodstream (Rettig et al., 2012) . The main components of the ECM are collagens, laminins, fibronectin and proteoglycans among other types of glycoproteins, and seem to play an important role in the homeostasis of the BM (Travlos, 2006) as described above.
The first BMDSCs identified by Till and McCullough were haematopoietic stem cells responsible for the haemato/lymphopoiesis of the BM, which represent the most numerous population of stem cells in the BM. These cells express CD45, CD34, CD133 and CD117 as well as C-X-C chemokine receptor type 4 (CXCR4) and are lineage marker negative (lin-) (Gallacher et al., 2000) . Nonhaematopoietic stem cells such endothelial progenitor cells (EPCs) (Asahara et al., 1997 (Asahara et al., , 1999 and mesenchymal stem cells (MSCs) (Friedenstein et al. 1974 ) have also been identified. EPCs have the ability to differentiate in endothelial cells contributing to the neovascularisation in normal and pathological conditions. MSCs, first described as fibroblast colony-forming cells, can differentiate to osteoblasts, chondroblasts, adipocytes, and stromal cells. Freshly isolated MSCs and culture-expanded MSCs display different characteristics. Additionally, a population of highly plastic BM-derived cells, referred to as multipotent adult progenitor cells (MAPCs), was described in 2002. Cultured murine MAPCs are negative for CD34, CD44, CD45, c-Kit, major histocompatibility complex (MHC) I and MHCII, but they express low levels of fetal liver kinase 1, stem cells antigen-1, and THY-1 and higher levels of CD13 and stage-specific embryonic antigen 1 . These cells are able to differentiate into not only the mesenchymal lineage cells but also endothelium and endoderm Schwartz et al., 2002; Roobrouck et al., 2011) .
Since the first BM transplant was reported (Thomas and Epstein, 1965) , autologous and heterologous BM transplantation have been used with success for more than 50 years. Greater experience and further characterization of different BMDSC populations have opened a new translational field for certain incurable degenerative pathologies. In this sense, BM transplantation shows that BMDSCs have the ability to repopulate a variety of organs in irradiated hosts (Theise et al., 2000; Körbling et al., 2002; Quaini et al., 2002; Mezey et al., 2003; Nemeth et al., 2012) . They are able to migrate to injured areas and participate in tissue regeneration, but the detailed mechanism of cell incorporation as well as the role of the different types of BMDSCs contributing to this regeneration remains controversial. Cytokines and chemokines secreted by the damaged tissues are crucial for homing BMDSCs to injured sites (Kollet et al., 2003) . Stromal cell-derived factor-1 (SDF-1), the ligand for CXCR4 expressed on various BMDSCs, is described as a chemo-attractant central to the homing process (Wright et al. 2002) . Furthermore, we know that irradiation, chemotherapy, and hypoxia induce the expression and secretion of SDF-1, inducing the engraftment of BMDSCs in damaged tissues (Ponomaryov et al. 2000) .
The use of BMDSCs as advanced cell therapy is gaining momentum. In the murine AS model, mostly based on physical damage of the endometrium, several studies using total BMDSCs have demonstrated beneficial effects in terms of stem cell engraftment, differentiation into stromal and epithelial cells, and improvement in reproductive outcome (Alawadhi et al., 2014; Cervello et al., 2015; Liu et al., 2018) . Cervello et al. (2015) administered systemic or intrauterine human BMDSCs labeled with superparamagnetic iron oxide into mice with mechanically-induced AS. Cell engraftment and location were analyzed by Prussian blue staining, endometrial proliferation by Ki67 staining, and quantitative RT-PCR of marker genes. Labeled human cells seemed to engraft around small endometrial vessels in all damaged uterine horns regardless of the route of cell administration or timing. Quantification of iron-positive cells revealed that 0.59% and 0.65% of engrafted cells were present after intrauterine or tail vein injection, respectively. However, no cells were detected in spleen, liver or kidney. Therefore, we observed that systemically-or locally-injected CD133+ cells have the ability to home and engraft selectively in the damaged endometrium (Cervello et al., 2015) , significantly increasing the proliferation of neighboring cells. The expression of several well described paracrine molecules was compared, showing an upregulation of thrombospondin 1 (THBS1) (2.065 vs. 0.752-fold-change; P < 0.05) and downregulation of insulin-like growth factor-1 (IGF1) (0.651 vs. 0.995-fold-change; P < 0.05) in the treated damaged horns in comparison with non-treated damaged horns (Cervello et al., 2015) . In contrast, another group (Ong et al., 2018) did not observe stem cell engraftment after BMDSC injection and highlighted the paracrine effect of this stem cell therapy.
In searching PubMed and Ovid without language or date restrictions for articles with the terms Asherman syndrome, EA, autologous SC therapy, regenerative medicine, CD133+ cells and BMDSCs, we identified two articles (Nagori et al., 2011; Singh et al., 2014) reporting autologous BMDSC transplantation in human AS. In the first reported case, CD + 9, CD40+ and CD90+ autologous BMDSCs were placed into the endometrial cavity to successfully treat AS in a patient undergoing egg donation (Nagori et al., 2011) . However, questions arose from this study about the nature and mechanisms of action of the instilled cells, the importance of inducing tissue damage before instillation and whether ethical concerns were appropriately considered (Gargett and Healy, 2011 ). The second study described the direct placement of non-characterized mononuclear stem cells isolated by Ficoll density separation into the subendometrial zone trough transmyometrial injection with a needle at 2-3 sites (fundus, anterior and posterior); however, no reproductive outcomes were assessed (Singh et al., 2014) .
Phase I Clinical Trial with CD133+ BMDSCs
Cells derived from BM co-expressing CD133+ and vascular endothelial growth factor receptor 2 (VEGFR2) represent the EPC subpopulation (Urbich and Dimmeler, 2004) . EPCs can be mobilized to the circulation to improve neoangiogenesis of pre-existing endothelium and have been used in clinical trials for regenerative medicine in nonhematological applications (Rafii and Lyden, 2003) . These cells can contribute to neoangiogenesis during wound healing and limb ischemia, post-myocardial infarction, endothelialisation of vascular grafts, atherosclerosis, retinal and lymphoid organ neovascularisation and tumor growth (Rafii and Lyden, 2003) . For instance, cells isolated from the peripheral blood using CD133 antibodies enhanced angiogenesis, astrogliosis, axon growth and functional recovery in a mouse spinal cord injury model (Kamei et al., 2013) . CD133+ cells embedded in atelocollagen gel within a silicone tube were used to bridge a 15-mm defect in the sciatic nerve of athymic rats; nerves regenerated within 8 weeks and transplanted CD133+ cells differentiated into Schwann cells (Kijima et al., 2009) . Moreover, human G-CSF cells histologically and functionally enhanced recovery from skeletal muscle injury in a rat model, contributing to the environment for muscular regeneration (Shi et al., 2009) . Additionally, CD133+ have the capacity to differentiate into non-haematopoietic cell lineages (Badorff et al., 2003) and display long-term repopulation potential in SCID mice (Handgretinger et al., 2003) .
The Simon group reported on a prospective, experimental, noncontrolled, open-labeled study in 18 patients aged 30-45 years with refractory AS or EA (Santamaria et al., 2016) . A total of 16 patients completed the study. Before enrollment, eight of 11 patients diagnosed with AS and all patients diagnosed with EA had previously undergone a mean of two (range 1-9) hysteroscopies and two subsequent cycles of HRT with neither clinical nor sonographic improvements. During the trial, initial echographic and hysteroscopic diagnosis was performed in the proliferative phase following the American Fertility Society classification (The American Fertility Society, 1988). All patients received HRT for 2 months immediately after the surgery.
BMDSCs were then mobilized into peripheral blood after administration of recombinant human G-CSF at a dose of 10 μg/kg/day for 5 days. G-CSF is a cytokine extensively used for this purpose in both autologous and allogeneic donors. One day after the last injection, peripheral blood mononuclear cells were separated by apheresis through peripheral venous access and CD133+ cells were isolated. A mean of 124 million cells (range 42-236) were obtained. These cells were delivered into spiral arterioles, which abut the EndoSC niche, by catheterization. This delivery method represents an effective minimally-invasive approach to homogeneously instill cells next to the endometrial niche and seems to promote increased engraftment in a rodent model (Liu et al., 2018) .
Three months after stem cell instillation, the status of the endometrial cavity was re-scored with a second-look hysteroscopy and in some patients a third look was performed 5-6 months after stem cell instillation. All patients experienced an improvement in the disease scores and stages, although the cavity was not completely normalized in all cases. Specifically, all patients diagnosed with Stage III AS improved to Stage I, while one of the two patients affected with Stage II showed a completely normalized endometrial cavity and the other improved to Stage I. The remaining patients initially with Stage I improved in qualifying score.
Clinically, all the treated patients showed a significant improvement in terms of duration and intensity of the menstrual period, especially in the first 3 months. However, this effect seemed to decrease progressively from a mean of 5.06 days (ranging from 3 to 7 days) in the first month to 3.25 days (ranging from 1 to 3 days) in the third month after cell therapy. Menstrual volume assessed by number of pads used/day also decreased from a mean of 2.69 (ranging from 1 to 5) to 1.75 (ranging from 1 to 4). However, a statistically significant improvement in endometrial thickness was observed in AS patients from 4.3 mm (range 2.7-5.0 mm) to 6.7 mm (range 3.1-12 mm; P = 0.004) and in the EA group from 4.2 mm (range 2.7-5.0 mm) to 5.7 mm (range 5-12 mm; P = 0.03).
CD133+ BMDSCs correspond to circulating endothelial progenitors with the capacity to improve neoangiogenesis. As a matter of fact, a statistically significant increase in the number of blood vessels in the endometrium was observed 3 months after stem cell instillation, together with a visible histological improvement of the stromal and epithelial layers of the endometrium. However, this effect was less robust 6 months after the cellular therapy, as was observed with the duration and intensity of menses. No side effects related to treatment were observed during the study.
This study was designed as a pilot study where each patient represented its own control after failed surgery and ART. The functionality of the treated endometrium was assessed through the reproductive outcome of patients who underwent ART after stem cell therapy. Three patients became pregnant spontaneously, 2, 4 and 19 months after cell therapy, resulting in two healthy babies born and a miscarriage at the 17th week due to a premature rupture of membranes, 2 weeks after a chorionic villous sampling. Further, seven positive pregnancies were obtained after 14 embryo transfers, resulting in three biochemical pregnancies, and one miscarriage at the ninth week due to a chromosomally abnormal embryo identified after the analysis of the products of conception, one ectopic pregnancy and three healthy newborns out of two patients (one twin pregnancy). In one patient, embryo transfer was canceled due to chromosomal abnormalities in all of the embryos and, in another case, transfer was not performed due to failure of cell therapy.
In summary, all these findings suggest that stem cell therapy will play an important role in the treatment of incurable endometrial pathologies such as AS and EA, and possibly others. In this sense, the EMA has recently issued a positive opinion to consider CD133+ cells as the first Orphan Drug Designed (ODD) therapy for the treatment of AS, categorizing these cells as Advanced Therapy Medicinal Product (ATMP), and supervised phase I/II and III trials are being performed (COMP, 2017).
Mechanisms of action of EndoSC therapy
CD133+ are EPCs with the capacity to egress from the BM, migrate to the bloodstream and incorporate into tissues. However, without injury the incorporation rate is low (Crosby et al., 2000) . Moreover, the engraftment efficiency significantly differs among EPC subpopulations in therapeutic intravenous administration of cells, being higher for in vivo purified BM mononuclear cells or expanded EPCs (7-20% incorporation rate) compared to endogenously mobilized BM engrafted cells (2%) . Further, these CD133+ cells can migrate upon stimulation by VEGF and SDF (Bongiovanni et al., 2014) .
Nevertheless, the number of EPCs incorporated into ischemic tissue seems to be low, and the role and neovascularisation ability of this cell type has been thoroughly demonstrated. Therefore, different mechanisms of action seem to contribute to regenerating tissues, such as paracrine activity, EndoSC differentiation/cell fusion, endometrial resident stem cell recruitment/activation and endothelial differentiation (Urbich and Dimmeler, 2004) as shown in Figure 3 .
EPCs can upregulate arteriogenesis-releasing cytokines and growth factors such as VEGF, EGF, HGF, IGF1 and G-CSF (Urbich and Dimmeler, 2004) , which synergistically ameliorate tissue damage. Mice treated with CD133+ cells exhibit cell engraftment as well as an increase in proliferation and cytokine expression of THBS1 and IGFR-1 in the endometrium compared to non-treated mice (Cervello et al., 2015) . This rapid release of growth factors and cytokines modulates migration, proliferation, and angiogenesis, causing an immediate short-term effect (Ratajczak et al., 2013) . Interestingly, the paracrine effects can contribute to endothelial regeneration as well as endometrial resident stem cell recruitment/activation (Bongiovanni et al., 2014) that finally lead to tissue remodeling.
Moreover, differentiated CD133+ cells can induce in vitro capillary tube formation in a 3D collagen gel culture system and contribute to vascular remodeling in vivo (Suuronen et al., 2006; Ong et al., 2018) . Further, translineage commitment of EPCs to cardiomyocytes has been reported (Badorff et al., 2003) , although this process seems to be rare and controversial (Ma et al., 2006) . Alternatively, CD133+ cells may differentiate into cardiomyocytes through cell fusion with neonatal cardiac myocytes (Avitabile et al., 2011) . Finally, CD133+ cells secrete cytokines that promote migration, growth, and differentiation and can potentially recruit resident stem cells through a paracrine effect, as shown in certain types of EPCs (Urbich et al., 2005) . In a nutshell, SSC temporary engraftment stimulates cytokine secretion to encourage the paracrine environment.
Current and future clinical translation of MyoSCs
In the last decade, several studies have demonstrated the regenerative potential of MyoSCs and suggested a role for them in uterine homeostasis (Ono et al., 2007 , Teixeira et al., 2008 Maruyama et al., 2010) . In this context, Simon's group showed that MyoSCs might partially reconstitute the uterine wall by generating new muscle fibers from the myometrium as well as new vessels (Mas et al., 2015) . To date little is known about the biology of MyoSCs in the reproductive tract and their molecular characterization remains in its early phase.
In fact, although most studies focus on cellular activity, a universal marker that allows the identification of MyoSCs in the human uterus remains unidentified. Therefore, the physiological role of these cells in the regeneration of uterine tissue deserves further investigation.
Indeed, there is an urgent need for multidisciplinary research using cutting-edge in vitro techniques and in vivo models to determine the cellular and molecular mechanisms of myometrial biology. The current investigations, from hormones to TICs and genetic alterations, should not only improve our understanding of myometrial physiology and the complex mechanisms of morphogenesis and uterine remodeling, but also deepen our knowledge of pathologies and lead to the discovery of novel therapeutics targets.
To date, there are no medical therapies approved for the longterm treatment of uterine leiomyomas; surgical procedures, the main treatment for more than a century, are associated with high tumor recurrence and negative economic impacts to both patients and health care systems (Cardozo et al., 2012) . The recent clinical introduction of selective progesterone receptor modulators (sPRMs) that exert an agonist or antagonist effect on the progesterone receptor offer an alternative medical approach for patients who initially had a surgical indication (Donnez et al., 2014; Donnez and Dolmans, 2016) . In this way, sPRMs open new avenues in the medical therapy of leiomyomas. However, since the mechanisms of action of sPRMS and its long-term effects are poorly understood, we need further studies focusing on prevention strategies in genetically predisposed women and on avoiding recurrence in women with a family or personal history of this diagnosis.
With the concept of TICs, understanding the molecular and cellular mechanisms leading to tumor development is essential for identifying new non-surgical treatments. By determining the differential gene expression patterns as well as the paracrine interactions between TICs and differentiated cell populations, we might shift the focus of therapeutic interventions from the total leiomyoma cell mass to a small cell population, thereby transforming the field of uterine biology and medicine by targeting the critical molecules in specific pathways. Additionally, treatments targeting TIC populations through newer genetic technologies would not only treat current leiomyomas, but also could prevent the development and growth of new tumors with minimal side effects. This change could prevent one of the major causes of heavy menstrual bleeding without affecting ovulation or fertility potential. This future strategy would be based on cellular therapy, providing a model to investigate myometrial-derived diseases such as uterine leiomyoma, leiomyosarcoma or adenomyosis.
Future perspectives: treating with cells and tissues conditions that cannot be cured with drugs
Tissue engineering
Emerging regenerative medicine techniques include cell therapy (see Current State of Advanced Stem Cell Therapy in EndoSC Niche Pathologies), and tissue engineering (TE). Cell therapy is based on the application of specific cell populations to restore or reconstruct damaged tissues or organs, while TE encompasses the growth of cells on specific 3D structures using different supports or scaffolds (Badylak et al., 2012) .
Since 2008, several landmarks in uterine bioengineering have been achieved (for review see Campo et al., 2017) . Two early studies reported the use of muscle cells alone or in combination with collagen/matrigel scaffolds for the reconstruction of the uterine wall using autologous graft material for the repair of the uterus (Campbell et al. 2008; Lü et al., 2009) . Pioneering studies incorporating uterine decellularisation processes were published in 2014 (Hellström et al., 2014; Miyazaki and Maruyama, 2014; Santoso et al., 2014) . Decellularisation comprises the extraction of cells from a tissue, with not only the removal of the cellular fraction from whole organs, but also the preservation of the 3D ultrastructure of the ECM to maintain the architectural integrity of the tissue (Crapo et al., 2011) . Rat models have been used to demonstrate the functionality of a reconstructed organ by successful pregnancy (Santoso et al., 2014) , endometrial reconstitution through recellularisation (Miyazaki and Maruyama, 2014) , and implantation sites located within the regenerated regions (Hellström et al., 2014; Hellström et al., 2016) .
After the first steps toward uterine decellularisation (Hellström et al., 2014 ), Simon's group developed a protocol for the decellularisation of the pig uterus (Campo et al., 2017) . The protocol, using sodium dodecyl sulfate and Triton X-100, successfully converted pig uteri into an acellular bioscaffold with potential for subsequent recellularisation. The preservation of a reusable/functional extracellular uterine matrix with an intact vascular network was achieved. Furthermore, human SP cells (Cervelló et al., 2011) were able to recellularise small acellular disk scaffolds obtained from the decellularised organs.
These advances could provide critical support for the regeneration of whole or partial uterine tissue, leading to novel therapeutic solutions for the treatment of absolute uterine factor infertility. Moreover, uterine transplantation became a reality when the Brannström group published the first successful live birth after uterine transplantation (Hellström et al., 2017) . Although it is a milestone in reproductive medicine, the transplantation of the uterus is inherently limited by several known problems such as the lack of donor organs and the need for long-term immunosuppression after transplantation. Therefore, the creation of a bioengineered artificial uterus based on autologous cells from the putative recipients represents a natural progression of the field.
Ethical hurdles and biological limitations
Stem cell research offers great promise for the treatment of certain gynecological disorders owing to a unique ability to maintain, replenish and repair tissues. However, human stem cell research may also raise some controversies, such as consent to donate materials for research, development of early trials involved in stem cell therapies or monitoring of stem cell research (Lo and Parham, 2009) .
Important ethical considerations must be observed with the 3D cellular culture techniques that can partially mimic the organization and function of an organ from any type of stem cells. The range of these multiple uses and purposes also raises concerns regarding tissue donation, ensuring anonymity of samples, ownership and longterm storage and manipulation. Additionally, increasing interest from biotech and pharmaceutical companies necessitates a constant ethical review (Anonymous, 2017) .
Indeed, SSC clinical trials should adhere not only to the guidance of regulatory boards, but also to the ethical principles that guide all clinical research, such as informed and voluntary consent and an appropriate balance of risks and benefits (Li et al., 2014) . Due to the highly innovative type of intervention, the as yet limited experience in humans, and the hopes of patients having diseases with no effective treatments, additional ethical requirements are warranted in these clinical trials. Therefore, scientific and ethics reviews have to be coordinated to verify that participants understand the key features of the trial and to ensure the publication of negative findings (ISSCR, 2016) . Careful attention to consent may prevent future controversies (Lo et al., 2008; Kimmelman et al., 2016) .
As in any other medical field, charlatanism without any scientific proof-of-concept should be identified and unmasked. In 2012, a company named Célle began offering an exclusive and revolutionary service providing women with the opportunity to collect and preserve EndoSC from their menstrual fluid. The company suggested that these stem cells could later differentiate to any cell type needed for later use to treat pathologies from Parkinson's and Alzheimer's diseases to liver disorders and diabetes. While this company did not remain in business, it is possible that a number of consumers were defrauded by it.
Indeed, the US Food and Drug Administration recently initiated action against stem cell clinics and biotech companies claiming to have cures for serious diseases without any scientific or clinical proof of successful therapy, thereby taking advantage of vulnerable patients. Serious adverse events and visual loss associated with intravitreal stem cell injections have highlighted the problem of performing stem cell therapy with little oversight and no proof of efficacy (Kuriyan et al., 2017) . Therefore, to ensure that the emerging field of stem cell therapies fulfills its promise to patients in a safe and effective manner, it requires a commitment not only to the principles of evidence generation, but also to the ethical principles that guide any clinical research and practice.
Conclusion
The endometrium of menstruating species consists of a germinal basalis that regenerates a transient functionalis during each menstrual cycle. The sequential development of the receptivity status by the endometrial epithelium and then decidualisation by the stromal compartment may represent a differentiation stage of stem-progenitor cells. Currently, we know that endometrial regeneration in humans is based on two sources of progenitor stem cells: tissue-resident, located in specific niches around perivascular regions in human endometrium, and exogenous cells derived from the BM with a temporary capacity to engraft.
The existence of MyoSCs has been demonstrated through the SP methodology as well as specific SSC surface markers, supporting their multipotent nature, quiescence, self-renewal and differentiation potential in the MyoSC niche. The cellular events occurring in this specific microenvironment are mediated by growth factors and ovarian hormones acting through paracrine/autocrine mechanisms. However, developmental errors in the MyoSC niche, such as chromosomal abnormalities and genetic and epigenetic defects, could promote the development of TICs and thus contribute to myometrial tumors (e.g. leiomyoma, leiomyosarcoma). The main challenge remaining for scientists and clinician-scientists is in understanding the molecular and cellular mechanisms of MyoSCs and TICs and identifying new therapeutic targets for the prevention or treatment of related myometrial pathologies.
Basic research on EndoSC is paying off and advanced cell therapy is ready to play an important role in the near future. The first Phase I clinical trial using CD133+ BMDSCs for incurable EndoSC niche pathologies, such as AS and EA, has been concluded with satisfactory results in terms of safety and efficiency. Indeed, the EMA has issued a positive opinion on CD133+ BMDSCs as the first ODD therapy for the treatment of AS, categorizing these cells as ATMP, and supervised phase I/II and III clinical trials are being performed. TE of the human uterus by growing cells on specific 3D scaffolds or decellularising existing uterine tissue while maintaining tissue architectural structure and composition, holds promise since uterine transplantation is now possible.
While ethical hurdles and biological limitations exist, as Nobel laureate Marie Curie would say, 'Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less'.
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